human
respiratori
syncyti
viru
rsv
primari
caus
bronchopneumonia
infant
children
worldwid
clinic
studi
shown
earli
treatment
rsv
patient
ribavirin
improv
prognosi
even
use
drug
limit
due
myelosuppress
toxic
effect
furthermor
effect
vaccin
prevent
rsv
infect
current
unavail
thu
develop
highli
effect
specif
antivir
drug
preexposur
prophylaxi
andor
treatment
rsv
infect
compel
need
quest
new
rsv
inhibitor
work
evalu
antivir
activ
seri
various
substitut
hbenzo
triazol
deriv
cellbas
assay
sever
result
fairli
potent
concentr
inhibitor
rsv
infect
plaqu
reduct
assay
accompani
low
cytotox
human
highli
divid
lymphoidderiv
cell
primari
cell
line
contextu
inhibitori
effect
observ
rna
dna
virus
assay
suggest
specif
activ
rsv
result
reveal
lead
compound
activ
earli
phase
rsv
infect
cycl
understand
whether
interf
viru
attach
target
cell
viruscel
fusion
event
inhibitori
activ
test
rsv
mutant
strain
f
envelop
glycoproteinand
plasmidbas
report
assay
quantifi
bioactiv
viral
entri
also
perform
overal
biolog
result
conjunct
silico
model
studi
support
conclus
rsv
fusion
process
could
target
new
seri
compound
human
respiratori
syncyti
viru
rsv
primari
caus
bronchopneumonia
infant
children
worldwid
clinic
studi
shown
earli
treatment
rsv
patient
ribavirin
improv
prognosi
even
use
drug
limit
due
myelosuppress
toxic
effect
furthermor
effect
vaccin
prevent
rsv
infect
current
unavail
thu
develop
highli
effect
specif
antivir
drug
preexposur
prophylaxi
andor
treatment
rsv
infect
compel
need
quest
new
rsv
inhibitor
work
evalu
antivir
activ
seri
various
substitut
hbenzo
triazol
deriv
cellbas
assay
sever
result
fairli
potent
concentr
inhibitor
rsv
infect
plaqu
reduct
assay
accompani
low
cytotox
human
highli
divid
lymphoidderiv
cell
primari
cell
line
contextu
inhibitori
effect
observ
rna
dna
virus
assay
suggest
specif
activ
rsv
result
reveal
lead
compound
activ
earli
phase
rsv
infect
cycl
understand
whether
interf
viru
attach
target
cell
viruscel
fusion
event
inhibitori
activ
test
rsv
mutant
strain
f
envelop
glycoproteinand
plasmidbas
report
assay
quantifi
bioactiv
viral
entri
also
perform
overal
biolog
result
conjunct
silico
model
studi
support
conclus
rsv
fusion
process
could
target
new
seri
compound
viral
pneumonia
increas
health
problem
worldwid
incid
number
virus
known
induc
respiratori
diseas
expand
recent
year
lee
qureshi
human
respiratori
syncyti
viru
rsv
main
etiolog
agent
pneumonia
bronchiol
lower
respiratori
tract
infect
lrti
particular
rsv
lead
caus
acut
lrti
children
less
year
age
wang
et
al
noyola
et
al
respons
substanti
diseas
burden
elderli
similar
nonpandem
influenza
falsey
et
al
falsey
everi
year
pathogen
caus
million
lrti
annual
death
toll
rsvrelat
diseas
nair
et
al
rsv
transmiss
occur
mainli
eye
nose
rather
mouth
may
via
largeparticl
aerosol
droplet
requir
close
contact
viru
howev
seem
capabl
travers
distanc
smallparticl
aerosol
nevertheless
abl
remain
infecti
variou
environment
surfac
suggest
fomit
sourc
spread
characterist
impli
rsv
easili
spread
hospit
ward
commun
break
rsv
infect
potenti
nosocomi
rsv
infect
enhanc
crowd
pediatr
ward
occur
commun
outbreak
sinc
particularli
winter
earli
spring
great
proport
admiss
infant
lrtirel
diseas
shed
viru
particularli
high
titer
actual
prophylact
strategi
base
human
neutral
antibodi
rsv
avail
protect
newborn
babi
highrisk
preterm
infant
suffer
cardiovascular
diseas
immunodefici
felt
et
al
cardena
et
al
howev
approach
costli
unafford
public
health
system
worldwid
likewis
aerosol
ribavirin
synthet
guanosin
analog
avail
treat
rsv
replic
mechan
action
drug
base
inhibit
rna
transcript
ribavirin
character
broad
spectrum
antivir
activ
potenti
toxic
besid
rel
high
cost
ventr
randolph
moreov
use
ribavirin
still
limit
benefici
effect
clinic
outcom
remain
unprov
ohmit
et
al
snell
scenario
make
rsva
negativesens
singlestrand
envelop
rna
member
pneumovirida
familyan
import
target
research
develop
new
antivir
rsv
rna
genom
code
key
intern
structur
protein
matrix
protein
nucleoprotein
n
protein
requir
function
polymeras
complex
phosphoprotein
p
polymeras
l
nonstructur
protein
involv
evas
innat
immun
respons
extern
expos
transmembran
glycoprotein
small
hydrophob
protein
sh
attach
protein
g
fusion
protein
f
regulatori
protein
antitermin
protein
involv
transcriptionrepl
regul
rsv
entri
target
cell
mediat
two
glycoprotein
g
f
glycopolypeptid
pack
dens
layer
viral
surfac
togeth
third
small
hydrophob
polypeptid
sh
whose
function
remain
unknown
primari
adsorpt
viru
target
cell
gener
promot
g
protein
sialic
acid
residu
cell
surfac
protein
serv
receptor
viral
entri
facilit
fusion
f
protein
adopt
metast
prefus
conform
activ
form
attach
f
hostcel
factor
one
factor
trigger
protein
conform
rearrang
result
fusion
viral
cellular
membran
sinc
f
essenti
rsv
infect
human
elicit
neutral
antibodi
target
potent
recogn
prefus
conform
accordingli
conform
f
consid
ideal
vaccin
antigen
antibodi
small
molecul
disrupt
structur
function
constitut
activ
field
current
research
last
two
decad
start
sanna
et
al
group
design
synthes
test
biolog
activ
larg
number
hbenzo
triazol
deriv
phenotyp
screen
approach
biolog
evalu
differ
pharmacolog
target
hbenzo
triazol
hereaft
name
benzotriazol
deriv
briguglio
et
al
led
discoveri
compound
endow
vitro
select
activ
ssrnacompound
exhibit
specif
potent
activ
rsv
among
potent
one
carri
chlorin
atom
posit
heterocycl
scaffold
given
benefici
role
alogen
substitu
aim
potenti
antirsv
activ
benzotriazol
compound
paper
report
design
synthesi
amid
scheme
deriv
scheme
potenti
rsv
inhibitor
antivir
activ
rsv
eventu
relat
toxic
compound
cellbas
assay
next
describ
togeth
result
investig
aim
understand
mode
action
cell
plasmidand
computerbas
assay
final
result
antivir
select
dichlorophenylbenzotriazol
cytotox
antivir
activ
repres
dna
singlestrand
rna
doublestrand
genom
dsrna
virus
famili
obtain
cellbas
assay
also
report
see
supplementari
materi
compound
melt
point
mp
taken
open
capillari
hot
stage
digit
electrotherm
melt
point
apparatu
uncorrect
h
nuclear
magnet
reson
nmr
spectra
determin
cdcl
dmso
record
bruker
avanc
iii
nanobay
mz
varian
instrument
chemic
shift
tm
scale
report
part
per
million
ppm
downfield
tetramethylsilan
tm
use
intern
standard
chemic
shift
valu
report
ppm
coupl
constant
j
hertz
hz
signal
multipl
repres
singlet
scheme
synthesi
amid
scheme
synthesi
amid
doublet
dd
doubl
doublet
triplet
q
quadruplet
multiplet
assign
exchang
proton
oh
nh
confirm
addit
c
nmr
determin
dmso
record
mhz
bruker
avanc
iii
nanobay
mass
spectra
ms
perform
combin
hp
gcm
apparatu
scheme
synthesi
urea
deriv
combin
liquid
chromatographagil
seri
mass
select
detector
msd
column
chromatographi
perform
use
mesh
merck
silica
gel
light
petroleum
refer
fraction
bp
c
progress
reaction
retard
factor
r
f
puriti
final
compound
monitor
tlc
use
merck
commerci
plate
analys
indic
symbol
element
within
theoret
valu
acet
anhydrid
propion
anhydrid
butyr
anhydrid
benzoyl
chlorid
alkyland
arylisocyan
commerci
avail
sigma
aldrich
usa
prepar
follow
procedur
previous
describ
us
carta
et
al
gener
procedur
prepar
n
benzo
yl
phenyl
alkylcarboxamid
stir
suspens
mmol
appropri
anhydrid
acet
propion
butyr
anhydrid
ml
heat
c
cool
rt
dilut
equal
volum
water
ml
result
precipit
filter
wash
water
dri
afford
crude
product
purifi
flash
chromatographi
use
eluent
mixtur
petroleum
etherethyl
acet
ratio
besid
desir
compound
diacyl
deriv
also
collect
solid
compound
crystal
ethanol
melt
point
yield
analyt
spectroscopi
data
report
gener
procedur
prepar
n
benzo
yl
phenyl
prarylcarboxamid
stir
solut
mmol
anhydr
dimethylformamid
dmfa
ml
ad
dropwis
solut
dmfa
ml
appropri
rbenzoyl
chlorid
mmol
ratio
solut
stir
c
h
f
c
e
g
h
h
h
h
cool
obtain
solid
filter
water
ad
achiev
quantit
precipit
result
precipit
collect
filtrat
wash
water
crude
product
purifi
flash
chromatographi
cm
cm
peea
cm
pede
peea
pede
via
recrystal
ethanol
c
chloroform
methanol
pe
petroleum
ether
de
diethyl
ether
ea
ethyl
acet
gener
procedur
prepar
phenyl
arylure
stir
solut
mmol
anhydr
n
ndimethylformamid
dmfa
ml
mmol
ratio
requir
isocyan
ad
anhydr
n
ndimethylformamid
mixtur
stir
c
h
h
day
k
c
h
g
l
h
h
reaction
mixtur
cool
room
temperatur
precipit
directli
collect
filtrat
compound
liquor
mother
evapor
dryness
crude
product
tritur
ether
obtain
correspond
solid
purifi
either
recrystal
ethanol
c
fl
flash
chromatographi
use
mixtur
petroleum
ethyl
etherdiethyl
acet
e
k
mw
elem
anal
calc
c
h
n
found
c
h
n
c
h
n
found
c
h
n
compound
total
yield
mp
c
tlc
petroleum
etherethyl
acet
r
f
ir
nujol
cm
uv
etoh
max
nm
hnmr
cdcl
dmso
j
hz
j
hz
ch
co
j
hz
ch
co
q
j
hz
ch
q
j
hz
ch
j
hz
ch
j
hz
ch
cnmr
dmso
co
c
c
c
c
c
c
c
ch
ch
j
hz
j
hz
q
j
hz
ch
q
j
hz
ch
j
hz
ch
j
hz
ch
cnmr
dmso
c
c
ch
ch
gcm
mz
nbutyryln
phenyl
butyramid
c
h
cl
n
mw
elem
anal
calc
c
h
n
found
c
h
n
cell
line
purchas
american
type
cultur
collect
atcc
absenc
mycoplasma
contamin
check
period
hoechst
stain
method
virus
maintain
laboratori
propag
appropri
cell
line
virus
store
small
aliquot
c
use
exponenti
grow
cell
seed
initi
densiti
cellsml
plate
contain
medium
supplement
fetal
bovin
serum
fb
unitsml
penicillin
g
streptomycin
mdbk
bhk
cell
seed
initi
densiti
cellsml
respect
plate
contain
minimum
essenti
medium
earl
salt
meme
lglutamin
mm
sodium
pyruv
mgl
kanamycin
supplement
hors
serum
mdbk
fetal
bovin
serum
fb
bhk
cell
seed
initi
densiti
cellsml
plate
contain
dulbecco
modifi
eagl
medium
dmem
lglutamin
mgl
kanamycin
supplement
fb
cell
cultur
incub
c
humidifi
co
atmospher
absenc
presenc
serial
dilut
test
compound
test
medium
use
cytotox
antivir
assay
contain
appropri
serum
cell
viabil
determin
h
c
mtt
method
mdbk
bhk
cell
budg
et
al
compound
activ
base
inhibit
virusinduc
cytopathogen
exponenti
grow
cell
acut
infect
multipl
infect
moi
antivir
activ
yfv
base
inhibit
virusinduc
cytopathogen
cell
acut
infect
moi
compound
activ
bvdv
base
inhibit
virusinduc
cytopathogen
mdbk
cell
acut
infect
moi
incub
c
cell
viabil
determin
mtt
method
describ
pauwel
et
al
compound
activ
vsv
vv
rsv
determin
plaqu
reduct
assay
infect
cell
monolay
describ
sanna
et
al
virucid
activ
assay
incub
pfuml
rsv
either
c
h
mixtur
without
test
sampl
use
control
end
incub
period
sampl
serial
dilut
media
titer
determin
cell
high
dilut
compound
activ
viru
titer
determin
plaqu
assay
cell
dextran
sulfat
dilut
serial
dilut
meme
give
rang
compound
concentr
rsv
approxim
pfuwel
compound
dilut
ad
triplic
cell
well
plate
seed
previou
day
cell
per
well
day
post
infect
sampl
collect
extent
viral
replic
determin
enzymelink
immunosorb
assay
elisa
accord
manufactur
descript
bioo
scientif
rsv
kit
cell
monolay
incub
plate
concentr
h
c
remov
compound
two
gentl
wash
cell
infect
rsv
viru
adsorpt
cell
inoculum
remov
cell
overlaid
medium
incub
day
c
viru
titer
determin
plaqu
assay
confluent
monolay
cell
tissu
cultur
plate
infect
h
room
temperatur
proper
rsv
dilut
give
final
moi
adsorpt
monolay
wash
two
time
meme
medium
lglutamin
supplement
inactiv
fb
mm
sodium
pyruv
gl
kanamycin
mainten
medium
incub
medium
co
c
time
zero
cell
treat
compound
approxim
time
higher
ic
refer
h
infect
period
specif
time
point
h
post
infect
incub
period
monolay
wash
two
time
mainten
medium
incub
fresh
medium
h
postinfect
h
develop
cytopath
effect
cpe
evalu
microscop
sampl
collect
centrifug
frozen
c
viral
titer
determin
plaqu
assay
elisa
compound
inhibitori
effect
viruscel
bind
event
measur
immunofluoresc
perform
accord
method
describ
previous
modif
maric
et
al
briefli
cell
plate
prechil
h
c
medium
remov
serial
dilut
rsv
icecold
meme
ad
allow
bind
approxim
min
c
incub
period
monolay
wash
three
time
cold
pb
order
remov
unbound
viral
particl
fix
paraformaldehyd
presenc
bound
viru
detect
indirect
immunofluoresc
brief
incub
block
buffer
pb
normal
goat
serum
ng
cell
incub
dilut
primari
antibodi
rsv
monoclon
antibodi
abcam
cambridg
unit
kingdom
cell
wash
three
time
incub
dilut
alexa
fluor
antimous
secondari
antibodi
molecular
probe
eugen
oreg
seri
wash
cell
mount
vectashield
vector
laboratori
burlingam
ca
contain
dapi
imag
well
captur
zoe
fluoresc
cell
imag
biorad
rsv
viral
dilut
pfuml
premix
dextran
sulfat
icecold
mem
ad
cell
monolay
c
bound
detect
report
capabl
block
celltocel
rsv
spread
evalu
use
describ
method
monolay
cultur
cell
sixwel
dish
infect
rsv
moi
room
temperatur
h
adsorpt
period
monolay
wash
pb
overlaid
fresh
medium
ad
concentr
h
post
infect
h
post
infect
cell
examin
microscop
syncytium
format
effect
rsv
plaqu
number
assess
plaqu
reduct
assay
accordingli
monolay
cell
grown
plate
approxim
plaqueform
unit
pfu
rsv
ad
cell
immedi
follow
addit
variou
concentr
sampl
medium
also
ad
nontreat
well
noninfect
control
plate
incub
co
c
h
viru
adsorpt
inoculum
remov
infect
cell
overlaid
methylcellulos
medium
contain
variou
concentr
test
sampl
incub
day
c
syncytia
develop
day
fix
paraformaldehyd
solut
permeabil
immunostain
number
plaqu
control
inhibitor
experiment
well
count
cell
line
purchas
american
type
cultur
collect
manassa
va
maintain
dmem
supplement
vv
fb
c
co
cell
transfect
carri
use
lipofectamin
invitrogen
dual
splitprotein
cell
content
mix
assay
adopt
quantifi
extent
celltocel
fusion
mediat
rsv
fglycoprotein
purpos
cell
transfect
plasmid
dna
encod
egfprenilla
luciferas
dualsplit
fusion
protein
dsp
dsp
respect
kondo
et
al
one
cell
popul
receiv
plasmid
dna
encod
rsv
anoth
cell
popul
transfect
plasmid
dna
code
mev
f
h
protein
control
brindley
et
al
accord
protocol
yan
et
al
cell
popul
mix
equal
ration
h
transfect
incub
specifi
amount
hr
activ
reconstitut
luciferas
measur
cell
load
viviren
promega
min
simul
perform
amber
suit
program
case
et
al
model
structur
prefus
rsv
f
glycoprotein
taken
protein
data
bank
file
battl
et
al
compound
dock
proteinbind
site
use
autodock
morri
et
al
result
complex
energi
minim
converg
intermolecular
complex
solvat
energi
minim
use
combin
molecular
dynam
md
techniqu
pierotti
et
al
gibbon
et
al
genini
et
al
ns
molecular
dynam
md
simul
c
employ
system
equilibr
md
run
data
product
bind
free
energi
g
bind
rsv
fprotein
estim
resort
mmpbsa
approach
massova
kollman
implement
amber
accord
valid
methodolog
free
energi
calcul
molecular
speci
complex
protein
ligand
correspond
g
bind
comput
enthalp
contribut
h
bind
e
mm
g
sol
account
molecular
mechan
energi
contribut
van
der
waal
electrostat
interact
solvat
free
energi
conform
entropi
upon
proteinligand
bind
correspond
ic
valu
compound
obtain
fundament
relationship
g
bind
rt
log
comput
protocol
appli
simul
establish
potent
rsv
fprotein
inhibitor
complex
rsv
fprotein
comparison
purpos
synthet
rout
obtain
amid
amid
urea
deriv
describ
scheme
respect
aliphat
amid
obtain
good
yield
condens
known
anilin
b
appropri
anhydrid
acet
propion
butyr
anhydrid
c
h
deriv
obtain
togeth
respect
diacyl
compound
gener
ratio
aromat
amid
turn
obtain
gener
good
yield
reaction
anilin
b
appropri
benzoyl
chlorid
deriv
c
h
obtain
tabl
antirsv
activ
amid
amid
urea
vero
ribavirin
use
refer
inhibitor
data
repres
mean
valu
three
independ
determin
variat
among
duplic
sampl
compound
concentr
requir
reduc
viabil
mockinfect
cell
determin
mtt
method
day
b
compound
concentr
requir
reduc
plaqu
number
rsv
monolay
interest
result
bold
urea
deriv
yield
requir
isocyan
condens
anilin
c
h
workup
crude
product
purifi
recrystal
ethanol
flash
chromatographi
key
intermedi
prepar
follow
procedur
describ
carta
et
al
newli
synthes
phenylbenzotriazol
deriv
evalu
antirsv
activ
cellbas
assay
sever
compound
exhibit
signific
inhibitori
activ
ie
tabl
ec
valu
lower
compar
ribavirin
concomitantli
moder
low
cytotox
detect
almost
compound
cc
valu
mostli
high
micromolar
rang
cell
regard
spectrum
antivir
activ
relev
result
concern
potent
select
activ
ten
deriv
b
c
seven
deriv
e
f
e
f
two
urea
deriv
ec
rsv
rang
structureact
relationship
perspect
consid
amid
replac
hydrogen
atom
amino
group
aliphat
moieti
ie
methyl
ethyl
propyl
amid
compon
respect
reflect
good
increas
potenc
even
higher
potenc
coupl
higher
cytotox
ec
valu
vs
cc
valu
vs
tabl
contrari
presenc
two
acyl
substitu
amino
group
detriment
antivir
activ
essenc
result
demonstr
need
hydrogen
atom
amid
nitrogen
rsv
replic
inhibit
convers
case
aromat
amid
unsubstitut
phenyl
deriv
show
moder
activ
ec
wherea
introduct
three
methoxi
group
phenyl
moieti
electronwithdraw
group
posit
potenti
antirsv
activ
ec
tabl
hand
electrondonor
methyl
group
posit
led
pitfal
correspond
ec
valu
final
seri
amid
small
alkyl
group
nitrogen
gave
best
antivir
activ
substitut
phenyl
ring
use
electronwithdraw
three
methoxi
group
present
also
amid
show
diffus
antivir
activ
rsv
amin
aliphat
amid
e
f
aromat
amid
e
f
show
activ
rang
contrarili
case
deriv
one
best
activ
diacyl
deriv
e
f
compar
correspond
monoacyl
compound
b
c
probabl
due
differ
arrang
space
amid
chain
furthermor
also
seri
simpl
unsubstitut
phenyl
amid
substitut
electrondonor
group
c
respect
gener
exhibit
high
activ
ec
deriv
bear
three
methoxi
group
nitro
group
chlorin
atom
phenyl
moieti
f
respect
mostli
show
good
activ
ec
tabl
final
urea
deriv
two
aliphat
deriv
show
remark
activ
rsv
ec
valu
respect
aim
evalu
select
titl
compound
rsv
also
test
cytotox
antivir
activ
panel
altern
repres
positiveand
negativesens
singl
strand
rna
doublestrand
rna
dna
virus
see
tabl
supplementari
materi
among
compound
c
moder
activ
coxsacki
viru
ec
respect
h
show
activ
cell
infect
bovin
viral
diarrhea
viru
bvdv
ec
respect
concomitantli
overal
low
cytotox
profil
inhibitor
confirm
cell
line
sustain
altern
viru
replic
tabl
base
result
experi
describ
result
interest
compound
endow
potent
select
antivir
activ
rsv
ec
tabl
cc
valu
lower
continu
cell
line
differ
organ
speci
tabl
tabl
therefor
select
addit
studi
report
antivir
activ
test
enzymelink
immunosorb
assay
elisa
aim
demonstr
reduct
viral
antigen
presenc
activ
compound
noncytotox
concentr
singl
round
viral
infect
result
show
reduct
viral
antigen
ec
agreement
previou
plaqu
reduct
assay
data
analyz
possibl
compound
act
directli
viru
particl
lead
infect
inactiv
virucid
assay
rsv
virion
conduct
virucid
effect
neglig
test
concentr
either
c
c
signific
differ
titer
rsv
treat
two
differ
temperatur
observ
shown
figur
compound
test
concentr
time
higher
antivir
ec
indic
inhibitori
effect
detect
plaqu
reduct
assay
tabl
could
due
interfer
step
along
rsv
replic
cycl
establish
whether
abl
protect
cell
rsv
infect
preattach
assay
perform
incub
cell
monolay
concentr
employ
virucid
activ
assay
broad
spectrum
dnarna
inhibitor
interfer
pyrimidin
biosynthesi
pathway
use
neg
refer
compound
eventu
unbound
drug
wash
away
cell
infect
rsv
percent
infect
determin
day
result
figur
show
experiment
condit
fail
inhibit
rsv
infect
time
point
analyz
find
demonstr
pretreat
protect
cell
rsv
infect
determin
step
rsv
replic
cycl
target
time
addit
toa
experi
perform
rsvinfect
cell
expos
compound
differ
time
infect
seen
top
panel
figur
effici
inhibit
observ
earli
phase
infect
ie
h
infect
immedi
fail
exhibit
signific
antivir
activ
ad
later
time
h
infect
result
support
addit
toa
test
perform
two
activ
compound
ec
tabl
see
figur
supplementari
materi
confirm
activ
earliest
stage
viral
replic
viru
attach
target
cell
viruscel
fusion
event
attempt
discrimin
two
possibl
mechan
action
ie
viru
attach
cellfus
inhibit
kinet
viru
adsorpt
presenc
investig
immunofluoresc
assay
lowtemperatur
treatment
allow
bind
rsv
cell
surfac
receptor
prevent
intern
viru
particl
cell
accordingli
abil
interfer
viru
bind
examin
incub
rsv
cell
c
presenc
compound
report
bottom
panel
figur
neg
control
abl
block
viral
bind
condit
contrari
dextran
sulfat
rsv
entri
inhibitor
use
posit
control
effici
block
viral
attach
aggreg
result
led
us
specul
either
viruscel
fusion
uncoat
process
might
affect
antivir
action
syncytium
format
mechan
celltocel
infect
determin
viru
spread
common
featur
sever
lower
respiratori
infect
rsv
cell
fusion
multinucl
syncytia
format
cell
slough
order
ascertain
whether
abl
prevent
viru
spread
infect
syncytium
reduct
assay
perform
treat
monolay
differ
concentr
h
post
infect
pi
syncytia
format
assess
h
pi
left
panel
figur
show
big
syncytia
evid
untreat
monolay
h
pi
number
size
syncytia
decreas
dosedepend
manner
treat
cell
b
c
initi
phase
rsv
infect
control
two
major
glycoprotein
surfac
rsv
virion
attach
glycoprotein
g
fusion
glycoprotein
f
g
target
ciliat
cell
airway
f
caus
virion
membran
fuse
target
cell
membran
small
hydrophob
sh
protein
also
encod
human
respiratori
syncyti
viru
absenc
lead
viral
attenu
context
whole
organ
prevent
apoptosi
infect
cell
heminway
et
al
kahn
et
al
techaarpornkul
et
al
among
protein
pool
howev
f
protein
alon
suffici
mediat
viral
penetr
host
cell
subsequ
syncytium
format
rsv
infect
feldman
et
al
seen
figur
right
panel
effect
reduc
syncytia
area
number
concentr
evid
suggest
could
interfer
rsv
f
proteinmedi
syncytium
format
e
f
dextran
sulfat
inhibit
viral
attach
g
h
inhibit
viral
attach
bound
viru
detect
indirect
immunofluoresc
antig
monoclon
antibodi
follow
alexa
fluor
secondari
antibodi
e
c
g
green
nuclei
visual
use
b
f
h
blue
confirm
result
obtain
syncytium
reduct
assay
report
test
activ
cell
infect
rsv
strain
rsv
mutant
variant
contain
larg
delet
ablat
synthesi
sh
g
glycoprotein
nonetheless
infecti
replic
high
titer
tissu
cultur
karron
et
al
plaquereduct
assay
inhibit
rsv
activ
inhibitori
concentr
valu
compar
one
determin
wildtyp
strain
ec
tabl
analog
two
altern
potent
compound
test
condit
gave
compar
result
inhibitori
concentr
respect
data
support
hypothesi
involv
fusion
event
via
interact
rsv
fusion
f
glycoprotein
biolog
result
discuss
support
inhibit
viral
entri
involv
fusion
process
possibl
mechan
action
compound
investig
aspect
detail
test
plasmidbas
report
assay
yan
et
al
quantifi
bioactiv
viral
entri
nakan
matsuda
accord
experi
figur
right
panel
compound
abl
specif
inhibit
rsv
f
proteinmedi
membran
fusion
process
ec
valu
confid
interv
repeat
assay
use
two
altern
potent
compound
yield
complet
analog
result
figur
taken
togeth
data
point
interfer
protein
fmediat
membran
merger
underli
mechan
antirsv
activ
compound
silico
interact
rsv
f
glycoprotein
last
step
character
antivir
activ
put
bind
mode
onto
rsv
fprotein
predict
molecular
model
figur
accord
silico
experi
could
bind
threefold
symmetr
trimer
protein
prefus
state
calcul
ic
g
bind
kcalmol
bind
process
estim
enthalpydriven
h
bind
kcalmol
bind
kcalmol
respect
agreement
evid
rsv
fusion
inhibitor
battl
et
al
seen
figur
dichlorosubstitut
benzotriazol
moieti
encas
hydrophob
caviti
line
side
chain
protom
whilst
phenyl
ring
engag
stack
protom
b
favor
hydrophob
interact
side
chain
residu
protom
moreov
two
weak
yet
persist
hydrogen
bond
detect
figur
quantit
doserespons
celltocel
fusion
assay
use
dspchimer
report
protein
vivirenrenilla
luciferas
substrat
presenc
compound
black
fill
symbol
green
fill
symbol
red
fill
symbol
mev
measl
viru
f
h
glycoprotein
express
construct
open
symbol
includ
select
control
report
valu
normal
dmsotreat
sampl
express
mean
three
experi
standard
deviat
ec
valuesfor
three
compound
obtain
variabl
slope
regress
fit
respect
data
obtain
condit
employ
see
main
text
materi
method
section
protein
first
involv
oxygen
atom
ureid
group
backbon
nh
group
protom
c
altern
hbond
provid
ureid
nh
group
compound
side
chain
protom
b
accord
cellbas
assay
tabl
compound
exhibit
antivir
activ
compar
ec
thu
specul
two
compound
could
adopt
bind
mode
onto
trimer
rsv
fprotein
similar
propos
verifi
hypothesi
comput
approach
appli
complex
figur
expect
replac
cyclohexyl
ring
propyl
chain
lead
signific
variat
interact
spectrum
describ
inde
fundament
hydrogen
bond
nice
molecular
encas
protein
hydrophob
caviti
still
detect
along
entir
simul
trajectori
figur
accordingli
bind
energet
profil
utterlt
compar
calcul
complex
g
bind
kcalmol
h
bind
kcalmol
bind
kcalmol
ic
hand
replac
ureid
spacer
amid
moieti
allow
perform
hydrogen
bond
involv
compound
oxygen
atom
figur
despit
provid
good
affin
rsv
fprotein
calcul
ic
g
bind
kcalmol
although
slight
decreas
enthalp
contribut
detect
h
bind
kcalmol
compens
less
entrop
penalti
justifi
presenc
rigid
group
structur
respect
current
highli
potent
inhibitor
rsv
fusion
process
eg
battl
et
al
less
potent
sinc
somewhat
smaller
structur
abl
fulli
exploit
plethora
stabil
interact
underlay
bind
mode
eg
figur
c
specif
hydrophob
pocket
protom
consist
residu
side
chain
protom
b
properli
accommod
benzimidazol
moieti
favor
hydrophob
interact
morpholin
group
inhibitor
optim
protein
bind
exploit
specif
electrostat
interact
ie
posit
charg
hydrogen
atom
perform
perman
ionic
bridg
protom
c
oxygen
atom
engag
stabl
dipol
interact
sidechain
protom
b
actual
better
bind
perform
respect
relat
presenc
two
bulki
substitu
benzimidazol
ring
moieti
favor
interact
aromat
side
chain
protom
c
via
stack
b
group
perform
posit
hydrophob
interact
protom
b
protom
c
also
engag
hydrogen
bond
protom
c
correspond
bind
thermodynam
complex
format
ie
g
bind
kcalmol
h
bind
kcalmol
bind
kcalmol
reflect
high
affin
compound
bind
rsv
fprotein
calcul
ic
nm
good
agreement
correspond
experiment
valu
ic
nm
battl
et
al
summari
preliminari
computerassist
drug
design
result
reveal
possibl
bind
mode
onto
rsv
fprotein
justifi
molecular
level
lower
potenc
compound
respect
nanomolar
rsv
fprotein
inhibitor
suggest
optim
benzotriazol
ring
ureid
group
substitut
could
lead
second
gener
potent
rsv
inhibitor
effort
direct
current
ongo
laboratori
rsv
widespread
pathogen
caus
human
lower
respiratorytract
infect
peopl
age
despit
long
histori
safe
effect
cure
rsv
remain
elus
work
seri
new
deriv
synthes
test
antivir
activ
rsv
compound
gener
endow
high
activ
ec
low
micromolar
rang
low
cytotox
cc
high
micromolar
rang
high
rsv
select
wholeviru
cellbas
assay
among
entir
class
compound
identifi
possibl
lead
compound
potent
antirsv
activ
ec
high
rsv
select
interest
safeti
profil
continu
cell
line
differ
organ
speci
select
activ
mechanist
studi
elisa
data
reveal
dosedepend
reduct
viral
antigen
noncytotox
concentr
whist
neglig
virucid
effect
found
rsv
virion
result
indic
compound
could
induc
signific
virion
inactiv
plaquereduct
assay
data
possibl
due
interfer
step
viral
replic
cycl
cell
pretreat
fail
prevent
viral
infect
time
drug
addit
assay
confirm
effect
inhibit
rsv
activ
infect
cell
ad
immedi
infect
result
support
hypothesi
could
inhibit
viral
infect
hamper
bind
penetr
process
viru
host
cell
discrimin
two
mechan
immunofluoresc
assay
perform
clearli
result
abl
block
viral
bind
cell
moreov
dosedepend
reduct
syncytia
area
number
led
final
specul
fusion
viral
envelop
cell
membran
mediat
rsv
f
glycoprotein
could
molecular
mechan
underli
antivir
activ
exert
confirm
hypothesi
activ
measur
cell
infect
rsv
strain
express
surfac
f
glycoprotein
instead
complet
pool
f
g
sh
glycoprotein
ec
compar
valu
measur
wildtyp
viru
indic
rsv
fglycoprotein
could
viral
molecular
target
subsequ
plasmidbas
report
assay
confirm
abl
specif
inhibit
rsv
f
proteinmedi
membran
fusion
process
ec
valu
final
molecular
simul
use
predict
put
bind
mode
onto
rsv
f
glycoprotein
prefus
state
three
protom
found
involv
bind
via
stabil
hydrogen
bond
hydrophob
interact
ultim
result
ic
valu
comparison
known
potent
rsv
fprotein
inhibitor
highlight
molecular
level
lower
potenc
compound
given
result
present
discuss
might
conclud
repres
promis
select
inhibitor
rsv
turn
could
consid
good
start
point
develop
secondgener
effect
candid
earli
treatment
rsv
infect
